CATB is a much better way to be long for the SRPT PDUFA.
CATB is trading at cash. They have a ph1/2 asset for DMD with randomized clinical data coming at the end of the year. If SRPT gets approved on Thursday, all DMD stocks, including CATB, are going up A LOT. If SRPT gets rejected, CATB will get hit as well, but given the valuation the downside is limited. Also CATB will present data on their NASH compound in a couple of months, and then there's data coming in DMD.
It's a 50/50 shot whether CATB is able to show something clinically significant in a relative short trial. However, the upside is huge, if they do.
Disclosure: I am/we are long CATB.